An engineered vaccine of the Plasmodium vivax Duffy binding protein enhances induction of broadly neutralizing antibodies

scientific article published on 23 October 2017

An engineered vaccine of the Plasmodium vivax Duffy binding protein enhances induction of broadly neutralizing antibodies is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1038/S41598-017-13891-2
P932PMC publication ID5653783
P698PubMed publication ID29062081

P50authorNiraj H ToliaQ55175593
Dhelio Batista PereiraQ56543847
Francis NtumngiaQ63639200
Samantha J BarnesQ89705262
Luzia Helena CarvalhoQ90459284
Camilla Pires de SouzaQ96212716
Richard Thomson-LuqueQ101237597
Miriam T GeorgeQ114412168
Flora S KanoQ114412170
John H. AdamsQ47150509
P2093author name stringChristopher L King
Darya Urusova
Jessica R S Alves
P2860cites workVivax malaria in Mauritania includes infection of a Duffy-negative individualQ21034116
Red blood cell invasion by Plasmodium vivax: structural basis for DBP engagement of DARCQ21131367
The Resistance Factor to Plasmodium vivax in BlacksQ22250916
Plasmodium vivax clinical malaria is commonly observed in Duffy-negative Malagasy peopleQ24600330
Diversity and natural selection in Plasmodium vivax Duffy binding protein geneQ56379448
HIV-1 vaccine candidate ineffectiveQ56907412
Vaccine development strategies for improving immunization: the role of modern immunologyQ80020558
Immune effector mechanisms in malariaQ82383609
Increasing the potency and breadth of an HIV antibody by using structure-based rational designQ24631510
In vitro evaluation of the role of the Duffy blood group in erythrocyte invasion by Plasmodium vivaxQ24681976
Dimerization of Plasmodium vivax DBP is induced upon receptor binding and drives recognition of DARCQ27670749
The March Toward Malaria VaccinesQ28084325
Plasmodium vivax invasion of human erythrocytes inhibited by antibodies directed against the Duffy binding proteinQ28471832
Structural analysis of the synthetic Duffy Binding Protein (DBP) antigen DEKnull relevant for Plasmodium vivax malaria vaccine designQ28544738
Positive Darwinian evolution in human influenza A virusesQ28775815
The neglected burden of Plasmodium vivax malariaQ29618450
Vivax malaria: neglected and not benignQ29619167
Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1Q29619511
A family of erythrocyte binding proteins of malaria parasitesQ33198214
Safety and allele-specific immunogenicity of a malaria vaccine in Malian adults: results of a phase I randomized trialQ33264523
Plasmodium vivax and mixed infections are associated with severe malaria in children: a prospective cohort study from Papua New GuineaQ33344896
Severe Plasmodium vivax malaria: a report on serial cases from Bikaner in northwestern IndiaQ33383089
Mapping epitopes of the Plasmodium vivax Duffy binding protein with naturally acquired inhibitory antibodiesQ33676028
Pentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challengeQ33804531
Determination of the molecular basis for a limited dimorphism, N417K, in the Plasmodium vivax Duffy-binding proteinQ33918156
Naturally acquired and vaccine-elicited antibodies block erythrocyte cytoadherence of the Plasmodium vivax Duffy binding protein.Q34004570
Immunogenicity of a synthetic vaccine based on Plasmodium vivax Duffy binding protein region II.Q34260750
Allelic diversity and naturally acquired allele-specific antibody responses to Plasmodium falciparum apical membrane antigen 1 in KenyaQ34290806
Identification of the erythrocyte binding domains of Plasmodium vivax and Plasmodium knowlesi proteins involved in erythrocyte invasionQ34331219
Natural variation within the principal adhesion domain of the Plasmodium vivax duffy binding proteinQ34548865
Evidence for transmission of Plasmodium vivax among a duffy antigen negative population in Western Kenya.Q34573683
Plasmodium vivax infection among Duffy antigen-negative individuals from the Brazilian Amazon region: an exception?Q34644273
Design and immunogenicity of a novel synthetic antigen based on the ligand domain of the Plasmodium vivax duffy binding proteinQ35666191
Severe Plasmodium vivax malaria, Brazilian AmazonQ35804562
Conserved and variant epitopes of Plasmodium vivax Duffy binding protein as targets of inhibitory monoclonal antibodiesQ35805433
Targeting a Neutralizing Epitope of HIV Envelope Gp120 by Immune Complex VaccineQ36157711
A reliable ex vivo invasion assay of human reticulocytes by Plasmodium vivaxQ36225497
The domain on the Duffy blood group antigen for binding Plasmodium vivax and P. knowlesi malarial parasites to erythrocytesQ36367429
Immune responses to asexual blood-stages of malaria parasitesQ36412872
Naturally acquired Duffy-binding protein-specific binding inhibitory antibodies confer protection from blood-stage Plasmodium vivax infectionQ36751523
Role of Plasmodium vivax Duffy-binding protein 1 in invasion of Duffy-null AfricansQ36978062
Broadly neutralizing epitopes in the Plasmodium vivax vaccine candidate Duffy Binding ProteinQ36978206
Toward an AIDS vaccineQ37158259
A Novel Erythrocyte Binding Protein of Plasmodium vivax Suggests an Alternate Invasion Pathway into Duffy-Positive ReticulocytesQ37208395
Strain-specific duffy binding protein antibodies correlate with protection against infection with homologous compared to heterologous plasmodium vivax strains in Papua New Guinean childrenQ37333369
Conserved residues in the Plasmodium vivax Duffy-binding protein ligand domain are critical for erythrocyte receptor recognitionQ37595658
Structural basis of immune recognition of influenza virus hemagglutininQ37925554
Malaria vaccines and human immune responsesQ38854831
Primaquine resistance in Plasmodium vivaxQ38950998
Immunogenicity of single versus mixed allele vaccines of Plasmodium vivax Duffy binding protein region II.Q39115271
Plasmodium falciparum merozoite surface protein 3 is a target of allele-specific immunity and alleles are maintained by natural selectionQ39362543
Strong diversifying selection on domains of the Plasmodium falciparum apical membrane antigen 1 geneQ39362584
Epitope-specific humoral immunity to Plasmodium vivax Duffy binding protein.Q39746136
Immune Responses in MalariaQ40259888
Congenital malaria due to chloroquine-resistant Plasmodium vivax: a case reportQ40361430
Plasmodium vivax:a glimpse into the unique and shared biology of the merozoiteQ40441210
Antigenic drift in the ligand domain of Plasmodium vivax duffy binding protein confers resistance to inhibitory antibodiesQ45062896
Sulphated tyrosines mediate association of chemokines and Plasmodium vivax Duffy binding protein with the Duffy antigen/receptor for chemokines (DARC).Q45273570
Mapping binding residues in the Plasmodium vivax domain that binds Duffy antigen during red cell invasionQ45273574
Naturally acquired inhibitory antibodies to Plasmodium vivax Duffy binding protein are short-lived and allele-specific following a single malaria infectionQ47812027
Inhibitory properties of the antibody response to Plasmodium vivax Duffy binding protein in an area with unstable malaria transmissionQ47858810
Allelic polymorphisms in apical membrane antigen-1 are responsible for evasion of antibody-mediated inhibition in Plasmodium falciparumQ47864459
The erythrocyte binding motif of plasmodium vivax duffy binding protein is highly polymorphic and functionally conserved in isolates from Papua New GuineaQ47876528
Biochemical, biophysical, and functional characterization of bacterially expressed and refolded receptor binding domain of Plasmodium vivax duffy-binding proteinQ47880785
Age-dependent cellular immune responses to Plasmodium vivax Duffy binding protein in humansQ47911727
Anti-Plasmodium vivax duffy binding protein antibodies measure exposure to malaria in the Brazilian Amazon.Q48010530
Genetic polymorphism of the Duffy receptor binding domain of Plasmodium vivax in Colombian wild isolatesQ48031812
P275copyright licenseCreative Commons Attribution 4.0 InternationalQ20007257
P6216copyright statuscopyrightedQ50423863
P433issue1
P407language of work or nameEnglishQ1860
P921main subjectPlasmodium vivaxQ311376
P304page(s)13779
P577publication date2017-10-23
P1433published inScientific ReportsQ2261792
P1476titleAn engineered vaccine of the Plasmodium vivax Duffy binding protein enhances induction of broadly neutralizing antibodies
P478volume7

Reverse relations

cites work (P2860)
Q59129806Blood-stage Plasmodium vivax antibody dynamics in a low transmission setting: A nine year follow-up study in the Amazon region
Q94606197Dynamics of IgM and IgG responses to the next generation of engineered Duffy binding protein II immunogen: Strain-specific and strain-transcending immune responses over a nine-year period
Q92827824Identification and Characterization of Functional Human Monoclonal Antibodies to Plasmodium vivax Duffy-Binding Protein
Q64054791Identification of an Immunogenic Broadly Inhibitory Surface Epitope of the Plasmodium vivax Duffy Binding Protein Ligand Domain
Q56340290Immunization with Recombinant Plasmodium falciparum Erythrocyte Membrane Protein 1 CIDRα1 Domains Induces Domain Subtype Inhibitory Antibodies.
Q58754493On the Evolution and Function of Reticulocyte Binding Surface Antigen ()
Q55429433Structural patterns of selection and diversity for Plasmodium vivax antigens DBP and AMA1.